Current evidence for non-pharmaceutical, non-surgical treatments of canine osteoarthritis.

Osteoarthritis is a progressive degenerative disease process that affects a significant proportion of the canine population, impacting these animals' quality of life. Currently, there is no cure and treatment consists of managing the clinical signs of pain and reduced mobility. There are many treatments for canine osteoarthritis and in this review we discuss the evidence base behind non-pharmaceutical, non-surgical treatments of this disease.

Advances in the pharmaceutical treatment options for canine osteoarthritis.

Canine osteoarthritis is a significant cause of pain in many dogs and can therefore compromise animal welfare. As the understanding of the biology and pain mechanisms underpinning osteoarthritis grows, so do the number of treatments available to manage it. Over the last decade, there have been a number of advances in the pharmaceutical treatment options available for dogs with osteoarthritis, as well as an increasing number of clinical trials investigating the efficacy of pre-existing treatments.

Intraoperative anaesthetic complications in dogs undergoing general anaesthesia for thoracolumbar hemilaminectomy: a retrospective analysis.

Objective: To establish the incidence of intraoperative anaesthetic complications in dogs undergoing general anaesthesia (GA) for thoracolumbar hemilaminectomy (TH), to determine whether GA duration affects incidence of intraoperative complications and to identify associations between intraoperative complications.

Study Design: Retrospective observational study.

Animals: A total of 224 client-owned dogs of various breeds undergoing TH for intervertebral disc extrusion.

Effects of atipamezole dosage and timing of administration on recovery time and quality in cats following injectable anaesthesia incorporating ketamine.

Objectives: The aim of this study was to establish the optimum dosage and timing of administration of atipamezole in cats undergoing general anaesthesia incorporating ketamine to provide the shortest recovery possible without unacceptably compromising recovery quality.

Methods: In total, 128 healthy male cats (age range 2-108 months, weight range 0.56-5.